Other Events ·
Aptevo Therapeutics Inc. announced a new solid tumor strategy on July 27, 2026, centered on a patent application for a…
APVOAptevo Therapeutics Inc.
Aptevo Therapeutics Inc. announced a new solid tumor strategy on July 27, 2026, centered on a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. This platform-derived innovation is designed to support multiple therapeutic approaches, including radiopharmaceuticals, T-cell engagers, and other immune-based therapies. The company intends to use this reusable targeting architecture to expand its oncology pipeline, enhance tumor localization, and increase opportunities for strategic partnerships with large pharmaceutical companies. Aptevo is a clinical-stage biotechnology company developing multispecific immuno-oncology therapeutics.